ArticleInternational journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics2026
Reducing inequities in access to postpartum hemorrhage prevention: Reframing advance distribution of misoprostol as a test case for health system responsiveness and adaptation.
Article in International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Advance distribution of misoprostol is an evidence-based strategy for preventing postpartum hemorrhage (PPH) at births without skilled health personnel present. Despite its lifesaving potential, initial momentum behind this intervention has slowed over the last decade and has not been renewed since WHO released updated guidelines in 2020 or the global Roadmap to combat postpartum hemorrhage between 2023 and 2030 was launched in 2023. The present article argues for renewed consideration of advance distribution of misoprostol in comprehensive PPH prevention strategies and reframing of policy dialogues around the intervention to reflect current health system realities and public health imperatives. Drawing on experiences of the Accelerating Measurable Progress and Leveraging Investments for Postpartum Hemorrhage Impact (AMPLI-PPHI) project across six diverse health systems, we position advance distribution of misoprostol as a litmus test for health system responsiveness and call on health sector stakeholders to critically examine all available opportunities to optimize PPH prevention strategies and accelerate efforts to reduce inequities in preventable maternal mortality.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.